Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Michael Makris on The Benefits of Low-Dose Emicizumab in Hemophilia A
Michael Makris/LinkedIn
Jan 19, 2026, 14:17

Michael Makris on The Benefits of Low-Dose Emicizumab in Hemophilia A

Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:

”Another study showing the benefit of low-dose emicizumab (Hemlibra) in hemophilia A.

The patients were receiving half the approved dose of the drug.

Despite this, the mean Annual Bleed Rate (ABR) was 0.4, the median was 0.0 and 67% had zero bleeds.

If you saw these data, you would not know that the patients were only using half the approved dose.

Is it not time for a randomised study in Europe or North America of full vs half-dose emicizumab in severe hemophilia A?

Roche will clearly never do such a study, it will need to be done independently.”

Michael Makris on The Benefits of Low-Dose Emicizumab in Hemophilia A

Stay updated with Hemostasis Today.

Annual Bleed Rate bleeding disorders Emicizumab Health Hematology Hemlibra Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine Michael Makris
NewsFeed